COVID-19 1st & 2nd dose vaccine – Moderna (18+), Pfizer-BioNTech (5+), Johnson & Johnson (18+, when available). see information below regarding children aged 5-11.
COVID-19 booster dose vaccine – Moderna (18+), Pfizer-BioNTech (18+), Johnson & Johnson (18+) see information below.
COVID-19 3rd dose vaccine – Moderna (18+ immunocompromised), Pfizer-BioNTech (18+ immunocompromised) see information below.
If you have already read and fully understand the recommendations, click here to sign up.
COVID-19 3rd dose vaccine for immunocompromised people.
Recently the FDA and the CDC authorized a 3rd dose COVID-19 vaccine for immunocompromised individuals. 3rd dose COVID-19 vaccines are available now at pharmacies, hospitals, clinics, and health departments across Iowa. The 3rd dose COVID-19 vaccine only applies to individuals who have completed the two-dose vaccine from either Moderna or Pfizer-BioNTech AND fit into an eligible category:
- Cancer treatment
- Organ transplant recipient that takes medication to suppress the immune system
- Received stem cell transplant in last 2 years
- Medication that suppresses the immune system
- Has an immunodeficiency (DiGeorge Syndrome, Wiskott-Aldrich Syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids
There are now booster recommendations for all three available COVID-19 vaccines in the United States. The CDC’s recommendations now allow for the mix and match dosing of booster shots. While some people may prefer to get a different booster, this will be dependent on the availability of COVID-19 vaccines on hand.
Moderna & Pfizer-BioNTech COVID-19 vaccine booster dose for all adults aged 18 years or older.
ACIP Expands Eligibility for COVID-19 Boosters in Persons with a Complete mRNA Series. The CDCs Advisory Committee on Immunization Practices (ACIP) expanded recommendations for booster shots to now include all adults ages 18 years and older who received a primary mRNA COVID-19 vaccine series (Pfizer-BioNTech or Moderna). In addition, ACIP updated recommendations for the groups who should receive a booster dose at least six months after completing the primary mRNA COVID-19 vaccine series to include:
Effective immediately, CDC recommends:
- Persons who should receive a COVID-19 booster dose:
- Ages 50 years and older who received an mRNA COVID-19 vaccine primary series.
- Aged ≥18 years and reside in long-term care settings who received an mRNA COVID-19 vaccine
- Persons who may receive a COVID-19 booster dose:
- Ages 18 years and older who received an mRNA COVID-19 vaccine primary series based on
individual benefit and risk, at least 6 months after primary series, under the FDA’s Emergency
Johnson & Johnson COVID-19 vaccine booster dose for adults aged 18 years and older.
Effective immediately, CDC recommends:
- People aged 18 years and older who received a single dose Johnson & Johnson primary series (1 dose) should receive a COVID-19 vaccine booster dose at least 2 months after completing the primary series.
- The Johnson & Johnson vaccine does not have eligibility criteria for the booster dose.
COVID-19 vaccines for 5 – 11-year-olds.
Effective immediately, the CDC recommends:
- A two-dose, primary vaccination series for everyone ages 5 years and older, regardless of a history of
symptomatic or asymptomatic SARS-CoV-2 infection or seropositivity. Pediatric Pfizer-BioNTech COVID-19
vaccine (2-doses, 10μg, IM) is recommended for children 5–11 years of age, under an Emergency Use
Authorization. COVID-19 vaccines may be administered without regard to the timing of other vaccines.
- This includes simultaneous administration of the COVID-19 vaccine and other vaccines on the same day.
Current or prior COVID-19 infection.
- People with known current SARS-CoV-2 infection should defer vaccination at least until the person has
recovered from the acute illness (if the person had symptoms) AND they have met the criteria to discontinue
- (Isolation and precautions can typically be discontinued 10 days after positive test if
asymptomatic or 10 days after symptom onset and after resolution of fever for at least 24 hours)
Serologic testing to assess for prior infection is not recommended for the purpose of vaccine